• Maze Therapeutics appointed Paula Johnson and Sophie Kornowski to its board.
• Johnson is president of Wellesley College, a cardiologist, and a Johnson & Johnson director; previously led Brigham and Women's women's health programs.
• Kornowski was CEO of Boston Pharmaceuticals from 2022, steering its liver-disease pipeline through its acquisition by GSK; formerly led partnering at Roche.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131642PRIMZONEFULLFEED9809956) on August 13, 2026, and is solely responsible for the information contained therein.